A citation-based method for searching scientific literature

Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
Times Cited: 776



Bradley J Monk, Andrés Poveda, Ignace Vergote, Francesco Raspagliesi, Keiichi Fujiwara, Duk-Soo Bae, Ana Oaknin, Isabelle Ray-Coquard, Diane M Provencher, Beth Y Karlan, Catherine Lhommé, Gary Richardson, Dolores Gallardo Rincón, Robert L Coleman, Thomas J Herzog, Christian Marth, Arija Brize, Michel Fabbro, Andrés Redondo, Aristotelis Bamias, Marjan Tassoudji, Lynn Navale, Douglas J Warner, Amit M Oza. Lancet Oncol 2014
Times Cited: 186




List of shared articles



Times cited

Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores.
K E Broekman, M van Kruchten, H van Tinteren, C Sessa, M Jalving, A K L Reyners. ESMO Open 2021
0


Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.
Bahar Yetkin-Arik, Arnoud W Kastelein, Ingeborg Klaassen, Charlotte H J R Jansen, Yani P Latul, Miloš Vittori, Aydan Biri, Korhan Kahraman, Arjan W Griffioen, Frederic Amant,[...]. Biochim Biophys Acta Rev Cancer 2021
5

Recent advancements of antiangiogenic combination therapies in ovarian cancer.
Daniel An, Susana Banerjee, Jung-Min Lee. Cancer Treat Rev 2021
0

Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening.
Quan Guo, Qing Yang, Jun Li, Guipeng Liu, Igor Nikoulin, Steve Jia. Anticancer Drugs 2020
3

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, Joern Rau, Philipp Harter, Florence Joly, Jalid Sehouli, Ulrich Canzler, Barbara Schmalfeldt, Andrew P Dean,[...]. Lancet Oncol 2020
25

Are antiangiogenics a good 'partner' for immunotherapy in ovarian cancer?
Elena García-Martínez, Andres Redondo, Josep Maria Piulats, Analía Rodríguez, Antonio Casado. Angiogenesis 2020
4